Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2

• DOI: 10.4103/jcrt.jcrt_782_23
• Publication Date: 2023-12-29T15:02:53Z
• Authors: Jun Wang; Liang Shao; Jing Liang; Qingming Wu; Baoli Zhu; Qiwen Deng; Zelin Liu; Liqiong Liu; Danyu Wang; Zhijian Yu; Xiaohua Tan; Fuxiang Wang; Jingye Meng; Xiaojun Xu; Zhongjun Xia; Zhiming Li; Hua Wang; Liang Wang; Wei Wu; Qi Xie; Xiaoxing Huang; Zhiqiang Sun; Yu Zhang; Hao Zhou; Hui Zhou; Wenyan Yang; Hua Ren; Zhe Liu; Mingqiang Qiao; Feifei Tang; Xiaofei Qi; Huijing Wu; Lijuan Deng; Li Gao; Hongyan Zhang; Peng Chen; Hongyu Zhang; Xinyou Zhang; Jihao Zhou; TU Chuanqing; Ling Guan; Qian Yin; Rong Shu; Feng Chen; Mingxin He; Qiang Wang; Zhi Guo
• Keywords: Microecology

In December 2022, the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became dominant in China due to its high infectivity and lower mortality rate. The risk critical illness among patients with hematologic malignancies who contracted SARS-CoV-2 was particularly high. aim this study draft a consensus facilitate effective treatments for these based on type severity disease. Following outbreak novel China, steering committee consisting experienced hematologists formed by Specialized Committee Oncology Microecology Chinese Anti-Cancer Association. expert group drafted management intervention measures different types clinical characteristics infection, along relevant guidelines literature. independent recommendations several important aspects epidemiology unique vulnerability malignancies. These included prophylactic vaccinations those malignancies, use plasma from blood donors recovered establishment negative pressure wards, steady-state mobilization peripheral hematopoietic stem cells, provision psychological support medical staff, focus maintaining healthy intestinal microecology.